Ablynx N.V. (NASDAQ:ABLYF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Ablynx N.V. (NASDAQ:ABLYF) traded up 3.09% on Friday, hitting $15.00. The stock had a trading volume of 800 shares. The stock’s market cap is $904.43 million. The company’s 50 day moving average is $14.36 and its 200-day moving average is $12.93. Ablynx N.V. has a 12 month low of $9.10 and a 12 month high of $15.30.

TRADEMARK VIOLATION WARNING: “Ablynx N.V. (ABLYF) Downgraded to “Sell” at Zacks Investment Research” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/08/ablynx-n-v-ablyf-downgraded-to-sell-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Ablynx N.V. (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ablynx N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx N.V. and related companies with MarketBeat.com's FREE daily email newsletter.